Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts' Corner
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, December 24, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Sirona Dental Systems Inc. (NASDAQ: SIRO), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Genomic Health Inc. (NASDAQ: GHDX), Unilife Corporation (NASDAQ: UNIS), and Stryker Corporation, Incorporated (NYSE: SYK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Sirona Dental Systems Inc. Research Report
On December 19, 2013, Sirona Dental Systems Inc.'s (Sirona) stock declined 0.44%, ending the day at $69.39. Over the previous three trading sessions, shares of Sirona increased 1.88%, compared to the Nasdaq Composite which increased 0.71% during the same period. The Full Research Report on Sirona Dental Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Ligand Pharmaceuticals Incorporated Research Report
On December 19, 2013, Ligand Pharmaceuticals Incorporated's (Ligand Pharmaceuticals) stock rose 2.44%, ending the day at $53.40. Over the previous three trading sessions, shares of Ligand Pharmaceuticals increased 3.29%, compared to the Nasdaq Composite which increased 0.71% during the same period. The Full Research Report on Ligand Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Genomic Health Inc. Research Report
On December 14, 2013, Genomic Health Inc. (Genomic Health) presented results from three studies of its Oncotype DX breast cancer test at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), highlighting unique value of the test in early-stage breast cancer. The Company stated that Oncotype DX remains the only genomic test to predict chemotherapy benefit, delivering clinically important and practice-changing information not provided by any other test. Executive Vice President of Research and Development for Genomic Health, Steven Shak, M.D., said, "Ten years ago, the first validation study of the Oncotype DX assay was presented at SABCS, ushering in a new era of personalized breast cancer treatment. Over the last decade, in partnership with many collaborators, we have demonstrated that the rigorous validation of genomic information can transform cancer treatment. Moving forward we will continue to apply our world-class science to lead the translation of massive amounts of genomic data into practice-changing results for treatment planning from screening and surveillance, through diagnosis, treatment selection and monitoring." The Full Research Report on Genomic Health Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Unilife Corporation Research Report
December 18, 2013, Unilife Corporation's (Unilife) Chairman and CEO Allan Shortall released a letter to the Company's shareholders informing about the resignation of Jim Bosnjak on November 21, 2013. The excerpts of the letter as follows, "Given that Jim embodies the spirit, drive and commitment to leadership that defines Unilife, we were delighted that he will continue to serve on our Board under the newly created roles of Deputy Vice Chairman and Lead Independent Director. On behalf of Unilife's entire Board and management team, I would like to take this opportunity to thank Jim for his guidance and support and look forward to his continued counsel." The letter further highlighted that the last few months have been transformational for the Company, with Unilife signing many new deals with pharmaceutical and biotechnology customers, which ensure the enhanced strength of the business as well make the Company well placed to generate billions of dollars in future revenue. Shortall's letter also stated, "To fully capitalize upon this significant opportunity, we have aggressively invested in R&D to develop the game-changing product platforms, advanced production systems and deep industry expertise to serve pharmaceutical companies under long-term partnerships. Because of our speed, agility and creativity, we have been able to out-innovate and out-perform the competition. Subsequently, a multitude of pharmaceutical and biotechnology companies now consider us to be a preferred partner for injectable drug delivery systems." Shortall's letter continued, "Recent agreements with Sanofi, Hikma, MedImmune and Novartis underline the long-term value that we can generate both for pharmaceutical customers and Unilife shareholders." The Full Research Report on Unilife Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Stryker Corporation, Incorporated Research Report
On December 17, 2013, Stryker Corporation, Incorporated (Stryker) announced the completion of its previously announced acquisition of MAKO Surgical Corp. (MAKO), a leader in the advancement of robotic arm assisted surgery in orthopaedics. President and CEO Kevin A. Lobo said, "We're excited to welcome MAKO into our organization and combine their expertise in robotic arm assisted surgery with Stryker's innovations in joint reconstruction to further advance the growth of this compelling technology. The long-term potential offered by this technology platform holds the promise of transforming reconstructive surgery, increasing patient satisfaction and enhancing the experience for surgeons and hospitals." According to the Company, as indicated in the September 25, 2013 press release, the transaction is expected to be dilutive to Stryker's adjusted EPS excluding acquisition and integration-related charges by approximately $0.10 - $0.12 in the first full year, neutral in year two and accretive thereafter. Stryker informed that the transaction is expected to be slightly accretive to adjusted cash EPS, excluding acquisition and integration-related charges in the first full year. The Full Research Report on Stryker Corporation, Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.